vs
Side-by-side financial comparison of FULTON FINANCIAL CORP (FULT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
FULTON FINANCIAL CORP is the larger business by last-quarter revenue ($336.2M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). FULTON FINANCIAL CORP runs the higher net margin — 28.2% vs 1.6%, a 26.5% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 4.2%). Over the past eight quarters, FULTON FINANCIAL CORP's revenue compounded faster (0.2% CAGR vs -0.2%).
Fulton Financial Corporation is an American regional financial services holding company, headquartered in Lancaster, Pennsylvania.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FULT vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $336.2M | $177.4M |
| Net Profit | $94.8M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 28.2% | 1.6% |
| Revenue YoY | 4.2% | 5.0% |
| Net Profit YoY | 1.9% | — |
| EPS (diluted) | $0.55 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.2M | $177.4M | ||
| Q4 25 | $336.0M | $196.9M | ||
| Q3 25 | $334.6M | $179.5M | ||
| Q2 25 | $324.1M | $181.1M | ||
| Q1 25 | $318.4M | $168.9M | ||
| Q4 24 | $319.6M | $187.3M | ||
| Q3 24 | $317.7M | $168.6M | ||
| Q2 24 | $334.7M | $178.0M |
| Q1 26 | $94.8M | $2.9M | ||
| Q4 25 | $99.0M | — | ||
| Q3 25 | $100.5M | $5.4M | ||
| Q2 25 | $99.2M | $-4.8M | ||
| Q1 25 | $93.0M | $4.8M | ||
| Q4 24 | $68.6M | — | ||
| Q3 24 | $63.2M | $-143.5M | ||
| Q2 24 | $95.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 35.7% | 1.2% | ||
| Q3 25 | 38.2% | 3.5% | ||
| Q2 25 | 37.8% | 4.7% | ||
| Q1 25 | 36.1% | 1.2% | ||
| Q4 24 | 27.0% | 13.2% | ||
| Q3 24 | 25.1% | -82.8% | ||
| Q2 24 | 30.8% | 15.9% |
| Q1 26 | 28.2% | 1.6% | ||
| Q4 25 | 29.5% | — | ||
| Q3 25 | 30.0% | 3.0% | ||
| Q2 25 | 30.6% | -2.7% | ||
| Q1 25 | 29.2% | 2.8% | ||
| Q4 24 | 21.5% | — | ||
| Q3 24 | 19.9% | -85.1% | ||
| Q2 24 | 28.4% | 10.6% |
| Q1 26 | $0.55 | $0.07 | ||
| Q4 25 | $0.53 | $0.05 | ||
| Q3 25 | $0.53 | $0.12 | ||
| Q2 25 | $0.53 | $-0.11 | ||
| Q1 25 | $0.49 | $0.10 | ||
| Q4 24 | $0.36 | $0.38 | ||
| Q3 24 | $0.33 | $-3.11 | ||
| Q2 24 | $0.52 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.5B | $653.9M |
| Total Assets | $32.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $3.5B | $653.9M | ||
| Q4 25 | $3.5B | $693.1M | ||
| Q3 25 | $3.4B | $727.2M | ||
| Q2 25 | $3.3B | $757.8M | ||
| Q1 25 | $3.3B | $798.5M | ||
| Q4 24 | $3.2B | $778.3M | ||
| Q3 24 | $3.2B | $749.6M | ||
| Q2 24 | $3.1B | $879.3M |
| Q1 26 | $32.2B | $1.2B | ||
| Q4 25 | $32.1B | $1.3B | ||
| Q3 25 | $32.0B | $1.3B | ||
| Q2 25 | $32.0B | $1.5B | ||
| Q1 25 | $32.1B | $1.6B | ||
| Q4 24 | $32.1B | $1.6B | ||
| Q3 24 | $32.2B | $1.5B | ||
| Q2 24 | $31.8B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FULT
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
